Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Nürnberg – page 21

505 clinical trials in Nürnberg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Nürnberg at a glance
505
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

505 trials in Nürnberg

Open in trial search

BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986365
  • Sponsor:AIO-Studien gGmbH

Systemic scleroderma

Not yet recruiting

Lebrikizumab in Adults with Moderate to Severe Localized Scleroderma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Pfizer Inc.

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CC-97540
  • Sponsor:Celgene Corp.

Colitis ulcerative

Not yet recruiting

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
  • Sponsor:Universitaetsklinikum Erlangen AöR

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:PROFIL Institut fuer Stoffwechselforschung GmbH

Gastrooesophageal cancer+1

Not yet recruiting

Study on the Safety and Effectiveness of Trastuzumab Deruxtecan with Drug Combination for Patients with HER2+ Resectable Esophagogastric Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Immune-mediated myositis

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel and Drug Combination for Patients with Severe Refractory Inflammatory Muscle Diseases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Cholangitis sclerosing

Not yet recruiting

Study on the Safety and Tolerability of Norucholic Acid Tablets for Patients with Primary Sclerosing Cholangitis (PSC)

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Norucholic Acid
  • Sponsor:Dr. Falk Pharma GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Nürnberg

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focused on treating multiple myeloma, breast cancer, and melanoma. Studies evaluate novel therapies including CAR T-cell treatments and targeted immunotherapies.

  • Multiple Myeloma Treatments
  • Breast Cancer Therapies
  • Melanoma Management

Advanced research includes investigation of new combination therapies and maintenance treatments post-transplantation.

02 Cardiovascular Studies

Innovative research targeting atherosclerotic cardiovascular disease and related conditions. Trials evaluate new medications for managing cholesterol and reducing major cardiovascular events.

  • Cholesterol Management
  • Cardiovascular Risk Reduction
  • Pulmonary Embolism Treatment

Focus on developing treatments to improve patient outcomes in cardiovascular conditions.

03 Immunology and Inflammation

Clinical studies examining treatments for inflammatory myopathies and psoriatic arthritis. Research focuses on innovative therapies and disease management approaches.

  • Inflammatory Disease Treatment
  • Autoimmune Conditions
  • Immunotherapy Applications

Emphasis on developing targeted treatments for severe inflammatory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.